Newsroom press releases

16/12/21 - 22:47

DiaSorin 2022-2025 Strategic Plan (552.15 KB)

Financial Data

30/11/21 - 19:10

DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)

Products Molecular

29/11/21 - 7:06

DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)

Products Immunodiagnostic

23/11/21 - 7:10

DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)

Products Immunodiagnostic

11/11/21 - 16:56

DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021 (862.48 KB)

Financial Data

18/09/21 - 8:16

DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)

Products Molecular

30/07/21 - 12:57

DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex (774.36 KB)

Financial Data

15/06/21 - 6:56

DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)

Products Immunodiagnostic

25/05/21 - 7:03

DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)

Products Immunodiagnostic

21/05/21 - 7:02

DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)

Products Molecular

20/05/21 - 8:27

DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)

Products Immunodiagnostic

14/05/21 - 16:10

DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021 (756.07 KB)

Financial Data

28/04/21 - 17:46

DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028 (529.64 KB)

Financial Data

28/04/21 - 7:54

DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028 (563.02 KB)

Financial Data

21/04/21 - 7:02

DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)

Products Immunodiagnostic

20/04/21 - 18:58

DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)

Products Immunodiagnostic

30/03/21 - 7:01

DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)

Products Immunodiagnostic

29/03/21 - 7:02

DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)

Products Immunodiagnostic

11/03/21 - 16:37

Dividend coupon date correction (414.99 KB)

Financial Data

11/03/21 - 15:31

Revenues, Profitability and Cash Flow Generation hit record highs in 2020 (748.06 KB)

Financial Data

23/02/21 - 6:11

DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)

Products Immunodiagnostic

11/01/21 - 18:43

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)

Products Immunodiagnostic